In the keynote speech at the ACO & Emerging Healthcare Delivery Coalition, Mark McClellan, MD, PhD, director of the Duke-Margolis Center for Health Policy, started out by providing a broad picture of Medicare reform before narrowing it down to what is happening on the ground.
In the keynote speech at the ACO & Emerging Healthcare Delivery CoalitionTM, Mark McClellan, MD, PhD, director of the Duke-Margolis Center for Health Policy, started out by providing a broad picture of Medicare reform before narrowing it down to what is happening on the ground.
The innovations in treatment—cures for hepatitis C, treatments for cancer that turn it into a chronic condition—have come with a higher cost. These big price tags aren’t a result of the cost savings that happen down the road by treating the disease, but reflect how people value living better and longer lives.
“What we really enjoy is more time … it’s really valuable,” McClellan said.
Medicare and Medicaid spending as a percentage of gross domestic product are currently 5%, and are on track to be 8% or 9% by the mid-2020s. This growth is happening because the American public is telling Congress to prioritize dollars spent toward healthcare, he said.
During his keynote, McClellan briefly touched on the impending presidential election, but mostly noted that there had not been a lot of talk during the presidential campaign about healthcare entitlements.
What is interesting is that there are some bipartisan healthcare proposals that he expects to garner more attention in January. There were 4 key areas where there is bipartisanship occurring:
1. More efficient biomedical innovation without compromising safety
2. Better evidence on what works through big data, collaborative networks, and better methods of turning data into evidence
3. Lower prices without limiting access to needed care
4. Changing healthcare delivery without reducing needed access to care
The Medicare Access and CHIP Reauthorization Act (MACRA) is another example of bipartisan collaboration. The new payment structure created under MACRA will have a large impact on providers, and those that participate in accountable care organizations (ACOs) stand to benefit. MACRA created 2 pathways: the Merit-based Incentive Payment System (MIPS) and advanced alternative payment models (APMs).
While the number of ACOs (currently, more than 600) is not expected to increase much, McClellan noted that the existing ACOs are expanding their reach and increasing the number of contracts they have.
In the coming years, he expects to see an increase again in the number of ACOs as MACRA kicks in. Providers in Medicare Shared Savings Program (MSSP) ACOs in tracks 2 or 3—which are considered advanced APMs—will be eligible for a 5% payment bonus beginning in 2019.
“If you want to be MIPS exempt in an advanced APM, the most important way to do that today is through ACO programs that take downside risk, or CMS has also identified a few bundled payment models that can qualify,” McClellan said.
Other than that, there aren’t too many options available to be eligible for advanced APMs and exempt from MIPS. He expects that will change though as additional pathways to advanced APMs in 2018 and beyond are added. For instance, CMS has proposed a MSSP Track 1+, which won’t have quite the level of downside risk as tracks 2 and 3. Track 1+ would have downside risk that is proportional to the practice revenue, which helps physician-led ACOs and smaller ACOs.
“The general theme of this regulation is very much wanting to make it easier for organizations that are not as big to do well in MIPS and APMs without creating big, consolidated groups,” McClellan said.
With the Medicare ACO program a few years old now, the industry is beginning to better understand what works. For instance, physician-led and integrated ACOs tend to do better, McClellan said, which is likely because they are closer to patients.
In addition, the ACOs that have been in the program for 3 or 4 years generated more savings, which is something both Patrick Conway, MD, chief medical officer of CMS, and Sean Cavanaugh, deputy administration and director of the Center for Medicare at CMS, had discussed during the National Association of ACOs fall meeting in September.
Still, building a successful ACO has proven to be hard. A lot of organizations that undertake the effort aren’t successful, and those that are don’t succeed right off the bat. The takeaway is that getting to success takes time.
“Organizations that stick with this can make it work,” McClellan said.
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More